Envestnet Asset Management Inc. Purchases 17,254 Shares of Natera, Inc. $NTRA

Envestnet Asset Management Inc. grew its position in Natera, Inc. (NASDAQ:NTRA) by 10.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 189,276 shares of the medical research company’s stock after buying an additional 17,254 shares during the quarter. Envestnet Asset Management Inc. owned 0.14% of Natera worth $30,468,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Sound Income Strategies LLC lifted its stake in Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC bought a new position in shares of Natera during the third quarter valued at approximately $46,000. Hilltop National Bank raised its stake in Natera by 59.8% in the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after buying an additional 116 shares in the last quarter. N.E.W. Advisory Services LLC lifted its holdings in Natera by 256.8% during the second quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after buying an additional 226 shares during the period. Finally, Blue Trust Inc. boosted its position in Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NTRA. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 price target on the stock in a report on Monday, October 27th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a research report on Monday, January 12th. Finally, Piper Sandler lifted their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 6,939 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total value of $1,580,912.37. Following the sale, the chief financial officer owned 52,120 shares in the company, valued at $11,874,499.60. This represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 1,639 shares of Natera stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total transaction of $378,232.03. Following the sale, the insider owned 137,847 shares of the company’s stock, valued at approximately $31,810,952.19. The trade was a 1.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 455,899 shares of company stock worth $106,475,440. 5.63% of the stock is owned by company insiders.

Natera Price Performance

Shares of NTRA stock opened at $212.46 on Thursday. The business has a fifty day moving average of $231.82 and a 200 day moving average of $198.09. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm has a market capitalization of $29.39 billion, a price-to-earnings ratio of -92.78 and a beta of 1.64.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.